Physicians' Cancer Chemotherapy Drug Manual

Physicians' Cancer Chemotherapy Drug Manual 2011 - Libros de Medicina - Oncofarmacologia - 60,08

[1]  D. Lara,et al.  Acute lymphocytic leukemia , 2014 .

[2]  Neil J Sebire,et al.  Gestational trophoblastic disease , 2010, The Lancet.

[3]  G. Demetri,et al.  Soft tissue sarcoma. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  Naomi J Balamuth,et al.  Ewing's sarcoma. , 2010, The Lancet. Oncology.

[5]  A. Adjei,et al.  Small cell lung cancer. , 2008, Mayo Clinic proceedings.

[6]  D. Hochhauser,et al.  Bone and Soft‐Tissue Sarcomas , 2007 .

[7]  R. Figlin,et al.  Renal Cell Cancer , 2007, Cancer journal.

[8]  E. Estey,et al.  Acute Myelogenous Leukemia , 2005 .

[9]  Daniel J Sargent,et al.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Linch,et al.  Hodgkin's lymphoma , 2003, The Lancet.

[11]  R. Pollock,et al.  Soft Tissue Sarcomas , 2001, CA: a cancer journal for clinicians.

[12]  B. Druker,et al.  Chronic myelogenous leukemia , 2001, Current opinion in oncology.

[13]  Y. Chang,et al.  Kaposi's sarcoma. , 2000, The New England journal of medicine.

[14]  R. Motzer,et al.  Renal-cell carcinoma. , 1996, The New England journal of medicine.

[15]  G. Bonadonna,et al.  Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. , 1995, JAMA.

[16]  M. Dimopoulos,et al.  Waldenström's macroglobulinemia. , 1994, Hematology/oncology clinics of North America.

[17]  P. Bunn.  Cutaneous T cell lymphomas , 1994, BMJ.

[18]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[19]  S. Lippman,et al.  Head and Neck Cancer , 1993, Cancer Treatment and Research.

[20]  L. Norton,et al.  Metastatic breast cancer. Length and quality of life. , 1991, The New England journal of medicine.

[21]  W. Hryniuk,et al.  The calculation of received dose intensity. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  H. Kantarjian,et al.  Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. , 1987, The American journal of medicine.

[23]  Hryniuk Wm.  Average relative dose intensity and the impact on design of clinical trials. , 1987, Seminars in oncology.

[24]  N. Chiorazzi,et al.  mechanisms of disease Chronic Lymphocytic Leukemia , 2010 .

[25]  V. Devita.  The evolution of therapeutic research in cancer. , 1978, The New England journal of medicine.

[26]  A. Schwartz,et al.  Neuroblastoma and Wilms' tumor. , 1977, The Medical clinics of North America.

[27]  V. Devita,et al.  The use of drugs in combination for the treatment of cancer: rationale and results. , 1973, The New England journal of medicine.

[28]  John McGrath,et al.  Hodgkin’s Disease , 1933, JAMA.

[29]  H. Isaacs.  Germ Cell Tumors , 2013 .

[30]  Renato Martins,et al.  Non-small cell lung cancer. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[31]  J. Leonard,et al.  Hodgkin's and Non-Hodgkin's Lymphoma , 2006 .

[32]  A. Swanson,et al.  The Key Extended Entry Program (KEEP): a methadone treatment program for opiate-dependent inmates. , 2001, The Mount Sinai journal of medicine, New York.

[33]  T. Greiner,et al.  Non-Hodgkin's lymphoma. , 2016, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[34]  Superficial bladder cancer. , 1992, The Urologic clinics of North America.

[35]  Devita Vt.  On the value of response criteria in therapeutic research. , 1988 .

[36]  D. Fisher,et al.  Hairy cell leukemia: a tumor of pre-plasma cells. , 1985, Blood.

[37]  Muggia Fm.  Primary chemotherapy: concepts and issues. , 1985 .

[38]  Erwin K. Kastrup,et al.  Drug facts and comparisons , 1977 .